New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%
HANGZHOU, Aug 19, 2022 – (ACN Newswire via SEAPRWire.com) – New Horizon Health (6606.HK), China’s leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today. Based on the financial information before the audit as of June 30, 2022, New Horizon Health achieved total revenue of RMB226... » read more